ClinVar Miner

Submissions for variant NM_001035.3(RYR2):c.839T>C (p.Leu280Pro) (rs794728716)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000182669 SCV000235048 uncertain significance not provided 2013-12-13 criteria provided, single submitter clinical testing p.Leu280Pro (CTA>CCA): c.839 T>C in exon 11 of the RYR2 gene (NM_001035.2). The Leu280Pro variant in the RYR2 gene has not been reported as a disease-causing mutation or as a benign polymorphism to our knowledge. Leu280Pro results in a semi-conservative amino acid substitution of a non-polar Leucine with a non-polar, sterically constrained Proline at a position that is conserved across species. In silico analysis predicts Leu280Pro is probably damaging to the protein structure/function. Furthermore, the Leu280Pro variant was not observed in approximately 6000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Leu280Pro is located in the N-terminal hotspot region of the RYR2 gene (Medeiros-Domingo A et al., 2009); however, no mutations in nearby residues have been reported in association with arrhythmia. With the clinical and molecular information available at this time, we cannot definitively determine if Leu280Pro is a disease-causing mutation or a rare benign variant. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is primarily an autosomal dominant disease characterized by progressive fibrofatty replacement of the myocardium that predisposes to ventricular tachycardia and sudden death (McNally E et al., 2009; Nava A et al., 2000). ARVC is most frequently caused by mutations in the genes encoding desmosomal proteins, complexes that maintain cell-to--cell connections and provide mechanical attachments among adjacent cells. Less commonly, ARVC may be caused by mutations in genes that encode proteins that maintain calcium homeostasis (McNally E et al., 2009). At least 11% of patients with autosomal dominant arrhythmogenic right ventricular cardiomyopathy were reported to have a mutation in the PKP2 gene (McNally E et al., 2009). Approximately 50% of patients with autosomal dominant Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) have been reported to have a mutation in the RYR2 gene, while mutations in the RYR2 gene associated with ARVC are rare (McNally E et al., 2009; Napolitano C et al., 2012). The variant is found in ARVC panel(s).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.